Circulating apoptotic and necrotic cell death markers in patients with acute liver injury

Liver International

Volumn 31, Issue 8, 2011, Pages 1127-1136

  Craig, Darren G N ^a   Lee, Patricia ^b   Pryde, Elizabeth A ^b   Masterton, Gail S ^a   Hayes, Peter C ^b   Simpson, Kenneth J ^b  

^a ROYAL INFIRMARY OF EDINBURGH   (United Kingdom)

^b UNIVERSITY OF EDINBURGH   (United Kingdom)

Author keywords

Acetaminophen; Acute liver failure; Apoptosis; Caspases; Liver transplantation; Nucleosomes

Indexed keywords

ALANINE AMINOTRANSFERASE; CYTOKERATIN 18; HIGH MOBILITY GROUP B1 PROTEIN; PARACETAMOL;

ACUTE LIVER INJURY; ADULT; ARTICLE; CELL DEATH; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG OVERDOSE; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HOSPITAL ADMISSION; HUMAN; LIVER INJURY; LIVER TOXICITY; LIVER TRANSPLANTATION; MALE; MULTIPLE ORGAN FAILURE; NUCLEOSOME; OUTCOME ASSESSMENT; PATHOGENESIS; PROGNOSIS; PROTEIN BLOOD LEVEL; SURVIVAL;

ACETAMINOPHEN; ADULT; AGED; ANALGESICS, NON-NARCOTIC; ANALYSIS OF VARIANCE; APOPTOSIS; BIOLOGICAL MARKERS; CHI-SQUARE DISTRIBUTION; DRUG-INDUCED LIVER INJURY; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HMGB1 PROTEIN; HUMANS; KERATIN-18; LIVER; LIVER FAILURE, ACUTE; LIVER TRANSPLANTATION; MALE; MIDDLE AGED; NECROSIS; NUCLEOSOMES; PEPTIDE FRAGMENTS; PREDICTIVE VALUE OF TESTS; PROGNOSIS; PROSPECTIVE STUDIES; SCOTLAND; SEVERITY OF ILLNESS INDEX;

EID: 79961209077     PISSN: 14783223     EISSN: 14783231     Source Type: Journal    
DOI: 10.1111/j.1478-3231.2011.02528.x     Document Type: Article

References (51)

1. Larson AM, Polson J, Fontana RJ, et al. Acetaminophen-induced acute liver failure: results of a United States multicenter, prospective study. Hepatology 2005; 42: 1364-72.
2. Bernal W. Changing patterns of causation and the use of transplantation in the United Kingdom. Semin Liver Dis 2003; 23: 227-37.
3. Zhang H, Cook J, Nickel J, et al. Reduction of liver fas expression by an antisense oligonucleotide protects mice from fulminant hepatitis. Nat Biotechnol 2000; 18: 862-7.
4. El-Hassan H, Anwar K, Macanas-Pirard P, et al. Involvement of mitochondria in acetaminophen-induced apoptosis and hepatic injury: roles of cytochrome c, bax, bid, and caspases. Toxicol Appl Pharmacol 2003; 191: 118-29.
5. Kon K, Kim JS, Jaeschke H, Lemasters JJ. Mitochondrial permeability transition in acetaminophen-induced necrosis and apoptosis of cultured mouse hepatocytes. Hepatology 2004; 40: 1170-9.
6. Ray SD, Mumaw VR, Raje RR, Fariss MW. Protection of acetaminophen-induced hepatocellular apoptosis and necrosis by cholesteryl hemisuccinate pretreatment. J Pharmacol Exp Ther 1996; 279: 1470-83.
7. Kass GE, Macanas-Pirard P, Lee PC, Hinton RH. The role of apoptosis in acetaminophen-induced injury. Ann N Y Acad Sci 2003; 1010: 557-9.
8. Tagami A, Ohnishi H, Hughes RD. Increased serum soluble fas in patients with acute liver failure due to paracetamol overdose. Hepatogastroenterology 2003; 50: 742-5.
9. Rutherford AE, Hynan LS, Borges CBS, et al. Serum apoptosis markers in acute liver failure: a pilot study. Clin Gastroenterol Hepatol 2007; 5: 1477-83.
10. Volkmann X, Anstaett M, Hadem J, et al. Caspase activation is associated with spontaneous recovery from acute liver failure. Hepatology 2008; 47: 1624-33.
11. Bechmann LP, Marquitan G, Jochum C, et al. Apoptosis versus necrosis rate as a predictor in acute liver failure following acetaminophen intoxication compared with acute-on-chronic liver failure. Liver Int 2008; 28: 713-6.
12. Hofer S, Brenner T, Bopp C, et al. Cell death serum biomarkers are early predictors for survival in severe septic patients with hepatic dysfunction. Crit Care 2009; 13: R93.
13. Bechmann LP, Jochum C, Kocabayoglu P, et al. Cytokeratin 18-based modification of the MELD score improves prediction of spontaneous survival after acute liver injury. J Hepatol 2010; 53: 639-47.
14. Urbonaviciute V, Furnrohr BG, Meister S, et al. Induction of inflammatory and immune responses by HMGB1-nucleosome complexes: implications for the pathogenesis of SLE. J Exp Med 2008; 205: 3007-18.
15. Holdenrieder S, Stieber P, Bodenmuller H, et al. Circulating nucleosomes in serum. Ann N Y Acad Sci 2001; 945: 93-102.
16. Lotze MT, Tracey KJ. High-mobility group box 1 protein (HMGB1): nuclear weapon in the immune arsenal. Nat Rev Immunol 2005; 5: 331-42.
17. Zeerleder S, Zwart B, Wuillemin WA, et al. Elevated nucleosome levels in systemic inflammation and sepsis. Crit Care Med 2003; 31: 1947-51.
18. Zhong XY, Gebhardt S, Hillermann R, et al. Circulatory nucleosome levels are significantly increased in early and late-onset preeclampsia. Prenat Diagn 2005; 25: 700-3.
19. Geiger S, Holdenrieder S, Stieber P, et al. Nucleosomes as a new prognostic marker in early cerebral stroke. J Neurol 2007; 254: 617-23.
20. Koutouzov S, Jeronimo AL, Campos H, Amoura Z. Nucleosomes in the pathogenesis of systemic lupus erythematosus. Rheum Dis Clin North Am 2004; 30: 529-58.
21. Benoit M, Fenollar F, Raoult D, Mege JL. Increased levels of circulating IL-16 and apoptosis markers are related to the activity of whipple's disease. PloS one 2007; 2: e494.
22. Holdenrieder S, Stieber P, von Pawel J, et al. Circulating nucleosomes predict the response to chemotherapy in patients with advanced non-small cell lung cancer. Clin Cancer Res 2004; 10(Part 1): 5981-7.
23. Trejo-Becerril C, Onate-Ocana LF, Taja-Chayeb L, et al. Serum nucleosomes during neoadjuvant chemotherapy in patients with cervical cancer. Predictive and prognostic significance. BMC Cancer 2005; 5: 65.
24. Holdenrieder S, Nagel D, Schalhorn A, et al. Clinical relevance of circulating nucleosomes in cancer. Ann N Y Acad Sci 2008; 1137: 180-9.
25. Roth GA, Lubsczyk BA, Pilz J, et al. Nucleosome serum levels in acute hepatic failure and MARS treatment. Transplant Proc 2009; 41: 4207-10.
26. O'Grady JG, Schalm SW, Williams R. Acute liver failure: redefining the syndromes. Lancet 1993; 342: 273-5.
27. Bernal W, Donaldson N, Wyncoll D, Wendon J. Blood lactate as an early predictor of outcome in paracetamol-induced acute liver failure: a cohort study. Lancet 2002; 359: 558-63.
28. Knaus WA, Draper EA, Wagner DP, Zimmerman JE. APACHE II: a severity of disease classification system. Crit Care Med 1985; 13: 818-29.
29. Simpson KJ, Bates CM, Henderson NC, et al. The utilization of liver transplantation in the management of acute liver failure: comparison between acetaminophen and non-acetaminophen etiologies. Liver Transplant 2009; 15: 600-9.
30. Kramer G, Erdal H, Mertens HJ, et al. Differentiation between cell death modes using measurements of different soluble forms of extracellular cytokeratin 18. Cancer Res 2004; 64: 1751-6.
31. Yantorno SE, Kremers WK, Ruf AE, et al. MELD is superior to King's college and Clichy's criteria to assess prognosis in fulminant hepatic failure. Liver Transplant 2007; 13: 822-8.
32. Ilmakunnas M, Tukiainen EM, Rouhiainen A, et al. High mobility group box 1 protein as a marker of hepatocellular injury in human liver transplantation. Liver Transplant 2008; 14: 1517-25.
33. McGregor AH, More LJ, Simpson KJ, Harrison DJ. Liver death and regeneration in paracetamol toxicity. Hum Exp Toxicol 2003; 22: 221-7.
34. Pierce RH, Franklin CC, Campbell JS, et al. Cell culture model for acetaminophen-induced hepatocyte death in vivo. Biochem Pharmacol 2002; 64: 413-24.
35. Decker P, Singh-Jasuja H, Haager S, Kotter I, Rammensee HG. Nucleosome, the main autoantigen in systemic lupus erythematosus, induces direct dendritic cell activation via a MyD88-independent pathway: consequences on inflammation. J Immunol 2005; 174: 3326-34.
36. Bernal W, Ma Y, Smith HM, et al. The significance of autoantibodies and immunoglobulins in acute liver failure: a cohort study. J Hepatol 2007; 47: 664-70.
37. Holdenrieder S, Eichhorn P, Beuers U, et al. Nucleosomal DNA fragments in autoimmune diseases. Ann N Y Acad Sci 2006; 1075: 318-27.
38. Mortensen ES, Fenton KA, Rekvig OP. Lupus nephritis: the central role of nucleosomes revealed. Am J Pathol 2008; 172: 275-83.
39. Fishbein TM, Liu J, Wang L, Li Y, Boros P. Increased apoptosis is specific for acute rejection in rat small bowel transplant. J Surg Res 2004; 119: 51-5.
40. Scaffidi P, Misteli T, Bianchi ME. Release of chromatin protein HMGB1 by necrotic cells triggers inflammation. Nature 2002; 418: 191-5.
41. Bell CW, Jiang W, Reich CF III, Pisetsky DS. The extracellular release of HMGB1 during apoptotic cell death. Am J Physiol Cell Physiol 2006; 291: 1318-25.
42. Wang H, Bloom O, Zhang M, et al. HMG-1 as a late mediator of endotoxin lethality in mice. Science 1999; 285: 248-51.
43. Ulloa L, Messmer D. High-mobility group box 1 (HMGB1) protein: friend and foe. Cytokine Growth Factor Rev 2006; 17: 189-201.
44. Antoine DJ, Williams DP, Kipar A, et al. High-mobility group box-1 protein and keratin-18, circulating serum proteins informative of acetaminophen-induced necrosis and apoptosis in vivo. Toxicol Sci 2009; 112: 521-31.
45. Martin-Murphy BV, Holt MP, Ju C. The role of damage associated molecular pattern molecules in acetaminophen-induced liver injury in mice. Toxicol Lett 2010; 192: 387-94.
46. Tsung A, Sahai R, Tanaka H, et al. The nuclear factor HMGB1 mediates hepatic injury after murine liver ischemia-reperfusion. J Exp Med 2005; 201: 1135-43.
47. Watanabe T, Kubota S, Nagaya M, et al. The role of HMGB-1 on the development of necrosis during hepatic ischemia and hepatic ischemia/reperfusion injury in mice. J Surg Res 2005; 124: 59-66.
48. Sunden-Cullberg J, Norrby-Teglund A, Rouhiainen A, et al. Persistent elevation of high mobility group box-1 protein (HMGB1) in patients with severe sepsis and septic shock. Crit Care Med 2005; 33: 564-73.
49. Urbonaviciute V, Furnrohr BG, Weber C, et al. Factors masking HMGB1 in human serum and plasma. J Leukoc Biol 2007; 81: 67-74.
50. Rouhiainen A, Tumova S, Valmu L, Kalkkinen N, Rauvala H. Pivotal advance: analysis of proinflammatory activity of highly purified eukaryotic recombinant HMGB1 (amphoterin). J Leukoc Biol 2007; 81: 49-58.
51. Bianchi ME. HMGB1 loves company. J Leukoc Biol 2009; 86: 573-6.